Krsnaa Diagnostics reported a decline in consolidated net profit for the first quarter of FY27 (quarter ended June 30, 2026), posting ₹166 million compared to ₹205 million in the corresponding period last year. Despite the dip in bottom-line figures, the company saw significant growth in its top line, with revenue rising to ₹2.35 billion from ₹1.9 billion year-on-year.

The company published these unaudited standalone and consolidated financial results on August 15, 2026. The newspaper advertisements were placed in Financial Express and Loksatta, pursuant to Regulation 47 read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The earnings call transcript was subsequently disclosed under Regulation 30 on August 19, 2026.

The divergence between revenue growth and profit contraction highlights a squeeze on operating margins. While EBITDA increased to ₹588 million from ₹513 million in the prior year, the EBITDA margin narrowed to 25% from 27%. This suggests that costs rose at a faster pace than revenues during the period, largely due to upfront infrastructure investments.

Financial Highlights

Operational Drivers and Margin Pressure

Management attributed the margin compression to the front-loaded nature of its infrastructure-led model. Approximately 4,000 personnel were onboarded for the Rajasthan project, including logistics staff for collection centers, ahead of full revenue realization. These fixed costs, including laboratory equipment and manpower, were incurred from day one while operating below mature utilization levels.

Excluding these new projects, the like-to-like business delivered stable margins broadly in line with previous quarters. Rajasthan contributed ₹26 crore in revenue during the quarter. Management expects this to grow significantly, with annualized guidance ranging between ₹100 crore and ₹150 crore for FY27, potentially reaching ₹175 crore as operations stabilize. The state now has 31 mother labs, 62 hub labs, and 1,228 collection centers operational.

Retail Business Growth

The retail segment emerged as a key growth engine, with revenue jumping 64% year-on-year to ₹193 million (₹19.3 crore), contributing approximately 9% of total group revenue. The network has expanded to over 4,000 touchpoints across seven states. While currently operating at a negative EBITDA due to ground fleet deployment costs, management expects the retail business to turn EBITDA positive by Q2FY27. The company aims for retail to contribute 10% to 15% of total revenue by the end of FY27.

Strategic Developments

Krsnaa Diagnostics secured a new contract for 34 CT scan centers across Himachal Pradesh, expanding its footprint from 12 centers established nearly 12 years ago. This project is predominantly cash-paying and provides revenue visibility for the next decade. Additionally, eight MRI centers in Maharashtra were inaugurated and operationalized during the quarter, with the remaining centers in the pipeline expected to go live by end-Q3.

The company also added 12 new NABH accreditations, bringing the total count of NABL, CAP, and ACR accreditations to 124. A strategic partnership with Apulki Hospital in Pune commenced operations, granting Krsnaa exclusive diagnostic rights for radiology and pathology, including super-specialty segments.

What the Numbers Show

The data reveals a clear decoupling between revenue expansion and profitability in the short term. Revenue grew by approximately 22%, significantly outpacing the 13.1% growth in EBITDA. This gap resulted in a margin compression of nearly 200 basis points. The net profit decline of 19% underscores that operational gains were not sufficient to offset the higher cost base driven by the Rajasthan rollout. However, the rapid growth in retail revenue (64%) and the establishment of large-scale infrastructure suggest that the current margin drag is temporary and linked to capacity building rather than structural pricing pressure.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE08LI01020/25c44263-0806-43d7-b17d-33ff393f11f2.pdf

Krsnaa Diagnostics has significantly expanded its diagnostic footprint in Himachal Pradesh by securing a Public Private Partnership (PPP) Agreement with the Director Health Services, Health & Family Welfare Department, Government of Himachal Pradesh. The deal involves setting up, operating, managing, maintaining, and reporting CT Scan Diagnostic Facilities at 34 Government Health Institutions across the state, replacing an earlier arrangement that covered only 12 institutions. This expansion underscores the company’s growing dominance in public-sector healthcare partnerships and reinforces its position as a preferred service provider for diagnostics in the region.

The agreement was disclosed on July 23, 2026, pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The project will be implemented on a PPP basis for an initial period of seven years, extendable by a further three years on mutually agreed terms. Notably, the contract operates on a majority cash basis, providing greater revenue visibility compared to purely reimbursement-based models.

Key Contract Details

The expansion from 12 to 34 institutions represents a substantial increase in operational scale for Krsnaa Diagnostics . The company described this as one of the largest government partnerships undertaken for CT Scan diagnostic services. The move demonstrates the company's ability to successfully renew and scale up existing contracts, aligning with its strategic focus on healthcare excellence and expanded geographic reach within Himachal Pradesh.

Strategic Implications

The shift to a majority cash basis is a material development for the company’s cash flow dynamics in the state. Unlike traditional government contracts that may rely heavily on delayed reimbursements, a cash-based model suggests immediate or near-immediate revenue realization from end-users, potentially improving working capital efficiency. The extension option of three years provides long-term stability, allowing for better amortization of capital expenditures required for setting up the new facilities.

This partnership consolidates Krsnaa Diagnostics' presence in Himachal Pradesh, a key market for rural and semi-urban healthcare expansion. By scaling up from 12 to 34 locations, the company is likely to achieve economies of scale in operations and maintenance, further strengthening its competitive moat against private players in the region. The absence of promoter interest or related-party transactions in this award ensures the deal is conducted at arm's length, reflecting genuine market demand for the company's services.